Question · asked by 1 review
Low dose naldemedine vs higher dose: Serious adverse eventsg
- Population
- people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
- Intervention
- Low dose naldemedine
- Comparison
- higher dose
- Outcome
- Serious adverse eventsg
Low dose naldemedine showed no clear difference in serious adverse eventsg compared with higher doses (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Low dose naldemedine vs higher doses Serious adverse eventsg · people with cancer irrespective of whether they are receiving palliative care and with opioid‐induced bowel dysfunction Low dose naldemedine showed no clear difference in serious adverse eventsg compared with higher doses (low certainty). Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving… (2022) · Cochrane Headline outcomes only | RR 0.25 [0.03, 2.17] | 1 study · 112 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.